MX2010012019A - Pharmaceutical product comprising a muscarinic receptor antagonist and a î²2-adrenoceptor agonist. - Google Patents

Pharmaceutical product comprising a muscarinic receptor antagonist and a î²2-adrenoceptor agonist.

Info

Publication number
MX2010012019A
MX2010012019A MX2010012019A MX2010012019A MX2010012019A MX 2010012019 A MX2010012019 A MX 2010012019A MX 2010012019 A MX2010012019 A MX 2010012019A MX 2010012019 A MX2010012019 A MX 2010012019A MX 2010012019 A MX2010012019 A MX 2010012019A
Authority
MX
Mexico
Prior art keywords
receptor antagonist
pharmaceutical product
muscarinic receptor
adrenoceptor agonist
active ingredient
Prior art date
Application number
MX2010012019A
Other languages
Spanish (es)
Inventor
Mete Antonio
Ford Rhonan
Mather Andrew
Wiley Katherine
James Bull Richard
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0808710A external-priority patent/GB0808710D0/en
Priority claimed from GB0900563A external-priority patent/GB0900563D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2010012019A publication Critical patent/MX2010012019A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is a selected muscarinic receptor antagonist, and a second active ingredient which is a β2-adrenoceptor agonist, of use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease and asthma.
MX2010012019A 2008-05-13 2009-05-12 Pharmaceutical product comprising a muscarinic receptor antagonist and a î²2-adrenoceptor agonist. MX2010012019A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0808710A GB0808710D0 (en) 2008-05-13 2008-05-13 New combination 296
GB0900563A GB0900563D0 (en) 2009-01-14 2009-01-14 New combination
PCT/SE2009/050525 WO2009139708A1 (en) 2008-05-13 2009-05-12 PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A β2-ADRENOCEPTOR AGONIST

Publications (1)

Publication Number Publication Date
MX2010012019A true MX2010012019A (en) 2011-03-04

Family

ID=41318921

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010012019A MX2010012019A (en) 2008-05-13 2009-05-12 Pharmaceutical product comprising a muscarinic receptor antagonist and a î²2-adrenoceptor agonist.

Country Status (11)

Country Link
US (1) US20110190309A1 (en)
EP (1) EP2315589A4 (en)
JP (1) JP2011520877A (en)
KR (1) KR20110010725A (en)
CN (2) CN102908624A (en)
AU (1) AU2009247021B2 (en)
BR (1) BRPI0912657A2 (en)
CA (1) CA2723909A1 (en)
MX (1) MX2010012019A (en)
RU (1) RU2010147881A (en)
WO (1) WO2009139708A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200825084A (en) * 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
CN102089304A (en) 2008-05-13 2011-06-08 阿斯利康(瑞典)有限公司 Quinuclidine derivatives as muscarinic M3 receptor antagonists
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
KR101845257B1 (en) 2011-02-07 2018-04-04 삼성전자주식회사 image sensor
JP2011195593A (en) * 2011-06-30 2011-10-06 Astrazeneca Ab Quinuclidine derivative as muscarinic m3 receptor antagonist

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL62140C (en) * 1942-12-16
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
GR1001529B (en) * 1990-09-07 1994-03-31 Elmuquimica Farm Sl Process for the obtainment of a new pregna-1,4-diene-3,20-dione -16-17-acetal-21 esters
US6223485B1 (en) * 1996-06-07 2001-05-01 Herman Miller, Inc. Wall panel system
CA2261692A1 (en) * 1996-07-29 1998-02-05 Rolf Johansson Arylcycloalkane carboxylic esters, their use, pharmaceutical compositions and preparation
US6613795B2 (en) * 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
EP1383730A2 (en) * 2001-04-03 2004-01-28 Aryx Therapeutics Anticholinergic compounds and methods of use
US7056916B2 (en) * 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
AR044134A1 (en) * 2003-05-02 2005-08-24 Novartis Ag DERIVATIVES OF QUINUCLIDINE, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS.
GB0424284D0 (en) * 2004-11-02 2004-12-01 Novartis Ag Organic compounds
TW200738658A (en) * 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
TW200738659A (en) * 2005-08-29 2007-10-16 Astrazeneca Ab Novel compounds
TW200825084A (en) * 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
WO2008059239A1 (en) * 2006-11-14 2008-05-22 Astrazeneca Ab Novel compounds 514
TW200833670A (en) * 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
GB0702457D0 (en) * 2007-02-08 2007-03-21 Astrazeneca Ab New combination 666
GB0702456D0 (en) * 2007-02-08 2007-03-21 Astrazeneca Ab New combination
GB0704000D0 (en) * 2007-03-01 2007-04-11 Astrazeneca Ab Salts 670
CN102089304A (en) * 2008-05-13 2011-06-08 阿斯利康(瑞典)有限公司 Quinuclidine derivatives as muscarinic M3 receptor antagonists
JP2011195593A (en) * 2011-06-30 2011-10-06 Astrazeneca Ab Quinuclidine derivative as muscarinic m3 receptor antagonist

Also Published As

Publication number Publication date
AU2009247021B2 (en) 2012-06-07
US20110190309A1 (en) 2011-08-04
EP2315589A1 (en) 2011-05-04
JP2011520877A (en) 2011-07-21
CN102088976A (en) 2011-06-08
EP2315589A4 (en) 2013-09-11
RU2010147881A (en) 2012-06-20
CN102088976B (en) 2012-12-26
AU2009247021A1 (en) 2009-11-19
KR20110010725A (en) 2011-02-07
CN102908624A (en) 2013-02-06
BRPI0912657A2 (en) 2016-01-26
CA2723909A1 (en) 2009-11-19
WO2009139708A1 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
MX2009008363A (en) Combination of a muscarinic receptor antagonist and a beta-2-adrenoceptor agonist.
IL193762A (en) Compounds useful in inhibiting dgat1-related disorders, pharmaceutical compositions comprising them and use thereof in preparation of medicaments
WO2007106181A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
MY178634A (en) Topical formulation for a jak inhibitor
IL233677A (en) Substituted benzisoxazole aminopyrazolo-pyrimidine compounds, pharmaceutical compositions comprising them and use of the compounds for the manufacture of medicaments
IL228017A0 (en) Substituted quinazolinone derivative, pharmaceutical composition comprising same and use thereof for preparation of a medicament
WO2012080729A3 (en) Casein kinase 1delta (ck1delta) inhibitors and their use in the treatment of neurodegenerative diseases such as tauopathies
MX2020012868A (en) Methods and compositions for sleep disorders and other disorders.
WO2007120270A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
WO2007120284A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
IL184932A0 (en) Glucagon receptor antagonists, preperation and therapeutic uses
HK1166983A1 (en) Solid forms comprising compounds for the treatment of diseases or disorders, compositions thereof, and use therewith
WO2009050136A3 (en) Glucocorticoid receptor antagonists such as mifepristone for treating cushing' s syndrome
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
UA92670C2 (en) Pyrazoline compounds as mineralocorticoid receptor antagonists , pharmaceutical use thereof, composition based thereon
HK1114013A1 (en) The combination of anticholinergics and leukotriene receptor antagonists for the treatment of repiratory diseases
IL211842A (en) Antibody or human tgfbrii-binding fragment thereof, pharmaceutical compositions comprising them and use thereof in the manufacture of medicaments for inhibiting angiogenesis
MX2013007622A (en) A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease.
GEP20186839B (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
UA93709C2 (en) 12-imidazolyl-1-dodecanol and use thereof in the preparation of pharmaceutical compositions
WO2007114855A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
WO2008026156A3 (en) Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor
IL200822A (en) (s)-2-amino-1-(4-chlorophenyl)-1-[4-(1h-pyrazol-4-yl)-phenyl]-ethanol compound, compositions comprising it and use thereof as medicaments and in the manufacture of medicaments for the treatment or prophylaxis of diseases mediated by some protein kinases
MX2010012019A (en) Pharmaceutical product comprising a muscarinic receptor antagonist and a î²2-adrenoceptor agonist.
EP2323656A4 (en) Pharmaceutical product comprising a muscarinic receptor antagonist and a beta-2-adrenoceptor agonist

Legal Events

Date Code Title Description
FG Grant or registration